Hydrazide containing nuclear transport modulators and uses thereof
US11034660B2 · kind B2 · utility
7Cited by
35References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 26, 2019 |
| Grant date | Jun 15, 2021 |
| Priority date | — |
| Expiry date | Nov 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.